Regencell Bioscience Holdings (RGC) Cash & Equivalents (2020 - 2024)

Regencell Bioscience Holdings (RGC) has 5 years of Cash & Equivalents data on file, last reported at $3.0 million in Q2 2024.

• Quarterly Cash & Equivalents rose 89.24% year-over-year to $3.0 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $3.0 million (up 89.24% YoY) and the FY2024 annual result came in at $3.0 million, up 89.24% from the prior year.
• Cash & Equivalents grew to $3.0 million in Q2 2024, from $1.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $6.4 million in Q2 2022 to a low of $59413.0 in Q2 2021.
• A 5-year average of $2.3 million and a median of $1.6 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents slumped 84.65% — and 2022, when it surged 10700.66%.
• Tracing RGC's Cash & Equivalents over 5 years: stood at $386979.0 in 2020, then tumbled by 84.65% to $59413.0 in 2021, then surged by 10700.66% to $6.4 million in 2022, then sank by 75.61% to $1.6 million in 2023, then jumped by 89.24% to $3.0 million in 2024.
• The last three Cash & Equivalents figures came in at $3.0 million (Q2 2024), $1.6 million (Q2 2023), and $6.4 million (Q2 2022), per Business Quant data.